SG/CALL/ELI LILLY & CO/1000/0.1/20.12.24 | Real-time Bid/Ask 04:52:32 2024-05-10 am EDT | ||
| 1.9 EUR / 1.93 EUR | -4.73% |
|
| Current month | +21.82% | ||
| 1 month | -28.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.89 | -5.97% | 0 |
| 24-05-09 | 2.01 | -0.99% | 0 |
| 24-05-08 | 2.03 | +15.34% | 0 |
| 24-05-07 | 1.76 | +30.37% | 0 |
| 24-05-06 | 1.35 | -10.00% | 0 |
Delayed Quote Börse Stuttgart
Last update May 10, 2024 at 03:21 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92X6 |
| ISIN | DE000SU92X63 |
| Date issued | 2024-02-29 |
| Strike | 1,000 $ |
| Maturity | 2024-12-20 (225 Days) |
| Parity | 10 : 1 |
| Emission price | 2.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.55 € |
|---|---|
| Lowest since issue | 1.35 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.6
USD
Average target price
850.4
USD
Spread / Average Target
+10.22%
- Stock Market
- Warrants
- Warrant